IMPACT OF RECOMBINANT HUMAN ERYTHROPOIETIN ON SYSTEMIC OXYGEN

重组人促红细胞生成素对全身氧的影响

• 批准号: 3765892
• 负责人: DALE C ALVERSON
• 金额: --
• 依托单位: UNIVERSITY OF NEW MEXICO
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3765892
• 关键词: anemia; blood disorder chemotherapy; erythropoietin; human subject; human therapy evaluation; oxygen consumption; oxygen transport; premature infant human; recombinant proteins

In conjunction with a multi-center core protocol to determine the impact of recombinant human erythropoietin (r-HuEPO) on the anemia of prematurity, this individual treatment center project is designed to determine the impact of r-HuEPO treatment on oxygen transport, oxygen delivery and overall oxygen utilization in preterm infants by serial measurement of the variables of SOT, P50, VO2, and calculation of O2 utilization in treated subjects and untreated controls and determine if there is a detectable physiologic benefit.

结合多中心核心方案确定影响 重组人促红细胞生成素（r-HuEPO）对 早产儿，这个个人治疗中心项目的目的是 确定r-HuEPO治疗对氧转运、氧 早产儿的分娩和总氧利用率 测量SOT、P50、VO 2变量，计算O2 在治疗受试者和未治疗对照中的利用率，并确定 存在可检测的生理益处。